´Þ¸¶µ¼Á¤15mg(Ç÷ç¶óÁ¦ÆÊ¿°»ê¿°) Dalmadorm Tab. 15mg
Àü¹®ÀǾàǰ | ±Þ¿©
|
ÇâÁ¤ÀǾàǰ
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
¿À·»Áö Ȳ»öÀÇ Çʸ§ÄÚÆÃµÈ ¿øÇü Á¤Á¦
Á¦Á¶È¸»ç
°í·ÁÁ¦¾à(ÁÖ)
ÆÇ¸Åȸ»ç
°í·ÁÁ¦¾à(ÁÖ)
Çã°¡Á¤º¸
Á¤»ó
(1999.08.05)
BIT ¾àÈ¿ºÐ·ù
¼ö¸éÁøÁ¤Á¦ ¹× ½Å°æ¾ÈÁ¤Á¦ (Hypnotics & Sedatives, minor tranquilizer)
º¹ÁöºÎºÐ·ù
112[ÃÖ¸éÁøÁ¤Á¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
642800250[G17000011] \43 ¿ø/1Á¤(2017.02.01) (ÇöÀç¾à°¡) \43 ¿ø/1Á¤(2014.02.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Flurazepam / N05CD01
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
¹Ì°áÁ¤¼¿·ê·Î¿À½º ,
»êÈÆ¼Åº ,
¼öÈ¿¡Æ¿¼¿·ê·Î¿À½º ,
½ºÅ׾Ƹ£»ê ,
½ºÅ׾Ƹ£»ê¸¶±×³×½· ,
¿Á¼ö¼öÀüºÐ ,
ÅÅÅ© ,
Æú¸®¿¡Æ¿·»±Û¸®ÄÝ400 ,
Æú¸®¿¡Æ¿·»±Û¸®ÄÝ6000 ,
Ȳ»ö»êÈö ,
È÷ÇÁ·Î¸á·Î¿À½º2910 ,
D-¸¸´ÏÅç
º´¿ë±Ý±â
Á¦Ç°º° ¿¬·É±Ý±â °í½Ã
¼ººÐ¸í
¼ººÐÄÚµå
ƯÁ¤¿¬·É
°í½Ã¹øÈ£
°í½ÃÀÏÀÚ
ºñ°í
flurazepam hydrochloride
161801ATB
15 ¼¼ ÀÌÇÏ
20090300
2009-12-03
¾ÈÀü¼º ¹× À¯È¿¼º ¹ÌÈ®¸³
Á¦Ç°º° ÀӺαݱ⠰í½Ã
1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ
¼ººÐ¸í
¼ººÐÄÚµå
±Ý±âµî±Þ
°í½Ã¹øÈ£
°í½ÃÀÏÀÚ
ºñ°í
flurazepam HCl
161801ATB
2
20160155
20161230
º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾à¹°ÀÇ ÃÖ±âÇü¼º »ç·Ê(´ëÁ¶±º¿¡ ºñÇØ ³ôÀ½), ½Å»ý¾Æ Æ÷À¯°ï¶õ, ±Ù±äÀåÀúÇÏ, Á¹À½, Ȳ´Þ Áõ°¡ ¹× ºÐ¸¸Àü ¿¬¿ë½Ã ½Å»ý¾Æ ±Ý´ÜÁõ»ó(½Å°æ°ú¹Î, ÁøÀü, °ú´Ù±äÀå µî) º¸°í.
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
642800250[G17000011]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\43 ¿ø/1Á¤(2017.02.01) (ÇöÀç¾à°¡)
\43 ¿ø/1Á¤(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
¿À·»Áö Ȳ»öÀÇ Çʸ§ÄÚÆÃµÈ ¿øÇü Á¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
500Á¤/º´
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
Æ÷ÀåÇüÅÂ
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
15¹Ð¸®±×·¥
500 Á¤
º´
8806428002501
8806428002525
15¹Ð¸®±×·¥
30 Á¤
º´
8806428002501
8806428002518
ÁÖ¼ººÐÄÚµå
161801ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
Àáµé±â ¾î·Æ°Å³ª, ¹ã¿¡ ÀÚÁÖ ±ú°Å³ª »õº®¿¡ ÀáÀÌ ±ú´Â ºÒ¸éÁõ, ¼ö¸éÈÞ½ÄÀ» ÇÊ¿ä·Î ÇÏ´Â ±Þ¸¸¼º º´Àû»óÅÂ
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : ¿°»êÇ÷ç¶óÁ¦ÆÊÀ¸·Î¼ 1ÀÏ 1ȸ 15§·À» ÃëħÀü¿¡ °æ±¸Åõ¿©Çϰí ÁßÁõÀÇ °æ¿ì¿¡´Â 30§·À» Åõ¿©ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë
[Á¶È¸]
±Ý±â
1) ±Þ¼º Çù¿ì°¢Çü ³ì³»Àå ȯÀÚ
2) ÁßÁõÀÇ ±Ù¹«·ÂÁõ ȯÀÚ
3) ÀÌ ¾à ¹× ´Ù¸¥ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾à¹° °ú¹ÎÁõ ȯÀÚ
4) ±Þ¼º È£ÈíºÎÀü ȯÀÚ
5) ¼ö¸é¹«È£ÈíÁõÈıº ȯÀÚ
6) 15¼¼ ÀÌÇÏÀÇ ¼Ò¾Æ
7) ¾ËÄÚ¿Ã ¶Ç´Â ¾à¹° ÀÇÁ¸¼º ȯÀÚ
½ÅÁßÅõ¿©
p class="indent0" >1) ´ÙÀ½ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀÌ ¿øÄ¢ÀÌÁö¸¸ Ưº°È÷ ÇÊ¿äÇÑ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. : Æó¼º½É, ¸¸¼ºÆó¼â¼ºÆóÁúȯ, ±â°üÁöõ½Ä ¹× ³úÇ÷°üÀå¾ÖÀÇ ±Þ¼º±â µî¿¡¼ È£Èí±â´ÉÀÌ ÀúÇÏµÈ °æ¿ì
2) ½ÉÀå¾Ö ȯÀÚ,
3) °£¡¤½ÅÀå¾Ö ȯÀÚ
4) ³úÀÇ ±âÁúÀû Àå¾Ö ȯÀÚ(ÀÛ¿ëÀÌ °ÇÏ°Ô ³ªÅ¸³².)
5) °í·ÉÀÚ(¿îµ¿½ÇÁ¶°¡ ³ªÅ¸³ª±â ½±´Ù.)
6) ¼è¾à ȯÀÚ
7) ô¼ö¼º ¶Ç´Â ¼Ò³ú¼º ¿îµ¿½ÇÁ¶ ȯÀÚ
8) ¾ËÄÚ¿Ã, ¼ö¸éÁ¦, ÁøÅëÁ¦, Ç×Á¤½Åº´¾à, Ç׿ì¿ï¾à, ¸®Æ¬¿¡ ÀÇÇÑ ±Þ¼º Áßµ¶ ȯÀÚ
ÀÌ»ó¹ÝÀÀ
1) ÀÇÁ¸¼º ¹× ±Ý´ÜÁõ»ó : º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾à¹°Àº Ä¡·áµµÁß ÀÇÁ¸¼ºÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, Àå±â°£ Åõ¿©È¯ÀÚ, °í¿ë·® Åõ¿©È¯ÀÚ, ƯÈ÷ ¾ËÄÚ¿ÃÁßµ¶·Â ȯÀÚ, ¾à¹°³²¿ë·Â ȯÀÚ, À̻󼺰ÝȯÀÚ ¶Ç´Â ÁßÁõÀÇ Á¤½ÅÁúȯÀÚ¿Í °°Àº ¼ÒÀμº ȯÀÚ¿¡¼ ÀÇÁ¸¼º ¹ß»ýÀ§Ç輺ÀÌ Áõ°¡µÇ¹Ç·Î ÀÇÁ¸¼º ¹ß»ýÀ§Ç輺À» ÃÖ¼ÒÈÇϱâ À§ÇØ ´ë»óÁúȯÀ» ÃæºÐÈ÷ °í·ÁÇÑ ÈÄ Åõ¿©ÇÑ´Ù. ±Ý´ÜÁõ»ó ¹ßÇö½Ã±â´Â Åõ¿©Áß´Ü ¼ö½Ã°£ ÈĺÎÅÍ 1ÁÖÀÏ ÈÄ ¶Ç´Â ±× ÀÌ»óÀ¸·Î ´Ù¾çÇϸç ÁøÀü, ºÒ¾ÈÁ¤, ºÒ¸é, ºÒ¾È, µÎÅë ¹× ÁýÁß·Â °á¿© µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ°í, µå¹°°Ô ¹ßÇÑ, ±ÙÀ° ¹× º¹ºÎ°æ·Ã, Áö°¢ÀÌ»ó, Çê¼Ò¸®, °æ·Ã µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ±Ý´ÜÁõ»óÀÌ ³ªÅ¸³ª¸é Áï½Ã ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þµµ·Ï Çϸç, °©ÀÛ½º·± Åõ¿©Áß´ÜÀ» ÇÇÇϰí, Á¡Â÷ÀûÀ¸·Î °¨·®ÇÏ¿© Åõ¿©ÇÑ´Ù.
2) Á¤½Å½Å°æ°è : ¶§¶§·Î Á¹À½, ºñƲ°Å¸², µÎÁß°¨, µÎÅë, µå¹°°Ô ¾îÁö·¯¿ò, ½Å°æ°ú¹Î, ÇôÀÇ ²¿ÀÓ, ÃÊÁ¶°¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) °£ : µå¹°°Ô °£Àå¾Ö(ºô¸®·çºó, ALT, AST, ALP »ó½Â)°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ¼øÈ¯±â°è : ¶§¶§·Î ¾àÇÑ Ç÷¾ÐÀúÇÏ, µå¹°°Ô ¼¸Æ, ½É°èÇ×Áø, °¡½¿¾²¸², ÈäÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ¼Òȱâ°è : ¶§¶§·Î ±¸°¥, ½Ä¿åºÎÁø, ±¸¿ª, º¯ºñ, À§ºÎºÒÄè°¨, ¾´¸À, º¹ºÎÆØ¸¸°¨, µå¹°°Ô ¼³»ç, Ÿ¾×ºÐºñ°ú´Ù µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) °ú¹ÎÁõ : ¶§¶§·Î ¹ßÁø µîÀÌ ³ªÅ¸³¯ ¼ö Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇØ¾ß ÇÑ´Ù.
7) °ñ°Ý±Ù : ¶§¶§·Î ÇǷΰ¨, ¹«·Â°¨ µîÀÇ ±Ù±äÀåÀúÇÏ, °üÀýÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) Ç÷¾× : µå¹°°Ô ¹éÇ÷±¸°¨¼ÒÁõ, °ú¸³±¸°¨¼ÒÁõ µîÀÌ º¸°íµÇ¾ú´Ù.
9) È£Èí±â°è : µå¹°°Ô È£Èí¾ïÁ¦°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶ÇÇÑ È£Èí±â´ÉÀÌ ½ÉÇÏ°Ô ÀúÇÏµÈ È¯ÀÚ¿¡°Ô Åõ¿©ÇÑ °æ¿ì¿¡ ź»ê°¡½º¿¡ ÀÇÇÑ È¥¼ö¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â ±âµµ¸¦ È®º¸Çϰí, ȯ±â¸¦ ÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
10) ±âŸ : µå¹°°Ô ¹ß¿, ¹ßÀû, Ư¼öÇÑ °æ¿ì¿¡ ¿ù°æºÒ¼øÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
»óÈ£ÀÛ¿ë
1) ´ÙÀ½ ¾à¹°°úÀÇ º´¿ë ¶Ç´Â À½ÁÖ¿¡ ÀÇÇÏ¿© ÀÌ ¾àÀÇ ÀÛ¿ëÀÌ Áõ°¡ µÉ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏÁö¸¸, ºÎµæÀÌÇÏ°Ô Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. : Æä³ëÄ¡¾ÆÁø°è ¾à¹°, ¹Ù¸£ºñÅ»°è ¾à¹° µîÀÇ ÁßÃ߽Űæ¾ïÁ¦Á¦, MAO ÀúÇØÁ¦
2) ÀÌ ¾àÀ» Æ÷ÇÔÇÑ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾à¹°°ú ¸¶¾à·ùÀÇ º´¿ëÅõ¿©´Â, »ó°¡ÀûÀÎ ÁßÃ߽Űæ°è ¾ïÁ¦ È¿°ú·Î ÀÎÇØ ÁøÁ¤, È£Èí¾ïÁ¦, È¥¼ö»óÅ ¹× »ç¸ÁÀÇ À§Ç輺À» Áõ°¡ ½ÃŲ´Ù. º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾à¹°°ú ¸¶¾à·ùÀÇ º´¿ëÅõ¿© ½Ã Åõ¿©¿ë·® ¹× Åõ¿©±â°£À» Á¦ÇÑÇϵµ·Ï ÇÑ´Ù.
3) µð¼³ÇǶ÷°ú º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡ ÀÌ ¾àÀÇ Ç÷Áß³óµµ°¡ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇØ¾ß ÇÑ´Ù.
4) º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾à¹°°ú µð°î½ÅÀ» º´¿ëÅõ¿©½Ã µð°î½ÅÀÇ ½Å¹è¼³ÀÌ ÁÙ¾îµé ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇØ¾ß ÇÑ´Ù.
5) ÀÌ ¾à°ú ½Ã¸ÞƼµòÀÇ º´¿ë½Ã ½Ã¸ÞƼµòÀÇ °£È¿¼Ò ¾ïÁ¦ÀÛ¿ëÀ¸·Î ÀÌ ¾àÀÇ Ã»¼ÒÀ²ÀÌ ÀúÇϵǾî ÀÛ¿ëÀÌ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
6) °£È¿¼ÒÀ¯µµÁ¦(¸®ÆÊÇǽеî)¿Í º´¿ë½Ã ÀÌ ¾àÀÇ Ã»¼ÒÀ²ÀÌ Áõ°¡µÈ´Ù.
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Xµî±Þ
(ÀӺΠÅõ¿© ±Ý±â )
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾à¶óº§
À̹ÌÁö
º¹¾à¼³¸í
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù.
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù.
*
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù.
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
Á¦ÇÑ¿¬·É±¸ºÐ (15¼¼ÀÌÇÏ)
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Flurazepam¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Pharmacology
Flurazepam¿¡ ´ëÇÑ Pharmacology Á¤º¸ Flurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.
Protein Binding
Flurazepam¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 83%
Half-life
Flurazepam¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours
Absorption
Flurazepam¿¡ ´ëÇÑ Absorption Á¤º¸ Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract
Pharmacokinetics
Flurazepam HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
¼ö¸éÈ¿°ú ¹ßÇö½Ã°£ : 15-20 ºÐ
ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 3-6 ½Ã°£
ÀÛ¿ëÁö¼Ó½Ã°£ : 7-8 ½Ã°£
´ë»ç : °£¿¡¼ Ȱ¼ºÃ¼ÀÎ N-desalkylflurazepamÀ¸·Î ´ë»çµÈ´Ù.
¹Ý°¨±â : ¼ºÀÎ : 40-114 ½Ã°£
Biotransformation
Flurazepam¿¡ ´ëÇÑ Biotransformation Á¤º¸ Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form
Toxicity
Flurazepam¿¡ ´ëÇÑ Toxicity Á¤º¸ Coma, confusion, low blood pressure, sleepiness
Drug Interactions
Flurazepam¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Amprenavir Amprenavir increases the effect and toxicity of benzodiazepineCimetidine Cimetidine increases the effect of the benzodiazepineClozapine Increased risk of toxicityEthotoin Possible increased levels of the hydantoin, decrease of benzodiazepineFluconazole Fluconazole increases the effect of the benzodiazepineFosphenytoin Possible increased levels of the hydantoin, decrease of benzodiazepineMephenytoin Possible increased levels of the hydantoin, decrease of benzodiazepinePhenytoin Possible increased levels of the hydantoin, decrease of benzodiazepineFosamprenavir Amprenavir increases the effect and toxicity of benzodiazepineIndinavir The protease inhibitor increases the effect of the benzodiazepineNelfinavir The protease inhibitor increases the effect of the benzodiazepineRitonavir The protease inhibitor increases the effect of the benzodiazepineSaquinavir The protease inhibitor increases the effect of the benzodiazepineItraconazole The imidazole increases the effect of the benzodiazepineKetoconazole The imidazole increases the effect of the benzodiazepineKava Kava increases the effect of the benzodiazepineOmeprazole Omeprazole increases the effect of benzodiazepineVoriconazole The imidazole increases the effect of the benzodiazepine
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Food Interaction
Flurazepam¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.Avoid alcohol.
Drug Target
[Drug Target]
Description
Flurazepam¿¡ ´ëÇÑ Description Á¤º¸ A benzodiazepine derivative used mainly as a hypnotic. [PubChem]
Drug Category
Flurazepam¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-anxiety AgentsGABA ModulatorsHypnotics and Sedatives
Smiles String Canonical
Flurazepam¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(CC)CCN1C(=O)CN=C(C2=CC=CC=C2F)C2=C1C=CC(Cl)=C2
Smiles String Isomeric
Flurazepam¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(CC)CCN1C(=O)CN=C(C2=CC=CC=C2F)C2=C1C=CC(Cl)=C2
InChI Identifier
Flurazepam¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
Chemical IUPAC Name
Flurazepam¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-30
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ